Sanofi Pasteur

Sanofi launches Shan5 paediatric pentavalent vaccine

Hyderabad - Sanofi Pasteur Monday announced the launch of its paediatric pentavalent vaccine Shan5, developed and manufactured by its affiliate Shantha here.

Shantha, a fully integrated biotechnology company involved in R and D, manufacturing and marketing, was acquired by Sanofi Pasteur Holding in 2009.

Shan5 is a fully liquid five-in-one convenient, safe and high quality vaccine that provides effective protection to children from six weeks of age against five diseases - diphtheria, tetanus, pertussis, Hib and hepatitis B.

The launch of Shan5 vaccine received prequalification status from the World Health Organisation (WHO) in April 2014, a press release from Sanofi said.

Syndicate content